Call for information – oxadiazon

[b]Information we are looking for [/b] The EPA is calling for information on the use of oxadiazon in Aotearoa New Zealand. This is an opportunity for you to provide information on oxadiazon-containing substances that are available in Aotearoa New Zealand, and how those substances are used. The information will help inform the EPA’s proposal to reassess oxadiazon, and any changes needed to ensure the rules match the risks and benefits. Some of the common products containing oxadiazon are: [size=200].[/size] Bowsar [size=200].[/size] Oracle [size=200].[/size] Foresite [size=200].[/size] Exadia [size=200].[/size] Weed Weapon Preventer [size=200].[/size] Granular or pelletised substance containing 20g/kg oxadiazon and 5 g/kg simazine [size=200].[/size] Suspension concentrate containing 380 g/litre oxadiazon We are looking for any relevant information industry, users, other interested parties, or the public can provide on the current use, practices, and benefits of oxadiazon-containing substances. This includes any information on: [size=200].[/size] the effects of the substances (positive or adverse effects) [size=200].[/size] toxicology [size=200].[/size] ecotoxicology [size=200].[/size] environmental fate studies [size=200].[/size] monitoring results.  As the current risk management framework is largely driven by industry requirements, we want to better understand current industry requirements such as: [size=200].[/size] identification and nature of the risks being managed [size=200].[/size] what measures are implemented to manage risks [size=200].[/size] the effectiveness of current requirements in managing risks to human health and the environment [size=200].[/size] how industry requirements align with other regulatory requirements under different pieces of legislation, such as the Hazardous Substances and New Organisms Act 1996 (HSNO Act), Health and Safety at Work Act 2015 (HSWA) and Resource Management Act 1991.   [b]The closing date to submit a response is 11.59 pm Tuesday 19 November 2024.  [/b]   [b]Responding to the call for information[/b] Please read the information below which outlines how the information provided will be used. You are welcome to answer all the questions or only those that are relevant to you. [b]Tables for part 3. Packaging and labelling and part 4. Use of oxadiazon products[/b]  If you’re likely to provide information on these questions, download this Word document now. [url=https://www.epa.govt.nz/assets/Uploads/Documents/Hazardous-Substances/Reassessments-programme/Oxadiazon-CFI/Oxadiazon-call-for-information-response-tables-APP204773.docx]Download the tables for Part 3: Packaging and labelling and Part 4: Use of oxadiazon products (DOCX, 136KB)[/url] Please include who the submission is from in the filename when you fill in and save the document. [b]Attach the supporting documents at the end of this form[/b] Please upload any documents for your submission at the end of this form. You do this on the next page, after clicking 'Continue'. Please also reference these documents in your responses.  [b]How we will use the information [/b] This information will be used to prepare an application for reassessment, to determine whether the EPA should undertake a modified or full reassessment of oxadiazon, and to inform that reassessment process. Interested parties will have an opportunity to make formal submissions on our assessment and proposal once an application has been lodged. [b]Your information may be made publicly available [/b] We may publish or otherwise make available all or part of your response. This may include your name but not your contact details. We acknowledge that some information may be commercially sensitive or be otherwise regarded as confidential. If you believe any of the information you are providing should not be made publicly available, please clearly indicate this within your response, and give the reasons, so we can consider this before publishing any information. [b]Privacy statement [/b] Any personal information you supply when providing information will be used only in relation to this call for information and subsequent reassessment application. You have a right to access and correct any personal information held by us, by contacting the EPA at [url=mailto:info@epa.govt.nz]info@epa.govt.nz[/url]. You may request that your personal information (such as your name) be withheld from publicly available information. We will not make your personal contact details publicly available. [b]Official Information Act [/b] The Official Information Act 1982(OIA) applies to all information held by the EPA (subject to section 55 of the HSNO Act), and information may be released under the OIA unless there are grounds to withhold it. If you consider any part of your response is confidential, please clearly label it as such and include the reasons why you think the information is confidential (for example, you may consider some information to be commercially sensitive). Further information on the OIA is at [url=http://www.ombudsman.parliament.nz/]www.ombudsman.parliament.nz[/url] Please fill in the form below, then click Continue to review your submission. At any time you may click Save and Exit so that you can return later.

You must provide either a company name or given name(s)

Part 1: Responder information
1.1 Are you representing your own views or the organisation that you belong to?
1.2 Please indicate which responder group(s) you belong to:
Part 2: Product information and quantities - If you have information on import or manufacture quantities, sales quantities, or oxadiazon use data for Aotearoa New Zealand, please answer this question.
Part 3: Packaging and labelling
Part 4: Use of oxadiazon products - If you use a product containing oxadiazon, please provide information on use patterns for different crops/applications, how much is used for each crop/application type, and whether this use corresponds to product label instructions or is an off-label use. You can download a Word document with tables to help you answer this question at the top this page. Fill in Table 2 Use of oxadiazon products.
Part 5: Mitigation measures and controls
Part 6: Impacts on Māori - In this section, we want to hear from Māori specifically about any impacts from the use of oxadiazon. We would like to hear from you if you are an iwi/hapū representative or represent your own views. Under section 6 of the HSNO Act, we are required to consider many factors including whether the use of oxadiazon affects the relationship of Māori and their culture and traditions with their ancestral lands, water, sites, wāhi tapu, valued flora and fauna, and other taonga. We must also consider any impacts on Māori rights accorded under the Te Tiriti o Waitangi (The Treaty of Waitangi).
Part 7: Key studies for EPA modelling - We are looking for key studies containing specific data to input into our aquatic, soil and human health risk assessment models for oxadiazon. This modelling might affect the reassessment outcome and the subsequent controls set for all substances containing the active ingredient. It is important that our modelling is done in a robust and comprehensive manner using the best data available.
7.1 Do you have any studies or technical reports on the toxicity of oxidiazon in relation to human health effects (particularly for the determination of the following classifications: suspected reproductive toxicity, suspected carcinogenicity, and specific organ toxicity)?
7.2 Do you have any studies or technical reports to assist the determination of acceptable operator limits?
7.3 Do you have any studies or technical reports to assist the determination of the ecotoxicity of oxadiazon to aquatic organisms (i.e. birds - acute and chronic toxicity)?
7.4 Do you have any studies or technical reports to assist the determination of the ecotoxicity of oxadiazon to soil-dwelling organisms and/or terrestrial vertebrates (i.e., birds - acute and chronic toxicity)?
7.5 Do you have any studies or technical reports to assist the determination of the environmental persistence and/or bioaccumulation potential of oxadiazon?
7.6 Do you have other studies or technical reports on oxadiazon’s toxicology, ecotoxicology, environmental fate, environmental monitoring data in New Zealand, and effects on public health/occupational health?
Part 8: Benefits and alternatives to oxadiazon products
Part 9: Hearing your views
Part 10: Confidential or commercially sensitive information
Back